Article
Radiology, Nuclear Medicine & Medical Imaging
Ashwin Singh Parihar, Lisa R. Schmidt, Farrokh Dehdashti, Richard L. Wahl
Summary: The aim of this study was to evaluate the detection rate of incidental second primary neoplasms in patients with prostate cancer on F-18-fluciclovine PET/CT. The results showed that 9.1% of patients had findings suggestive of a second neoplasm, with renal cell carcinoma being the most common (45.5%).
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Anna Karlberg, Lars Kjelsberg Pedersen, Benedikte Emilie Vindstad, Anne Jarstein Skjulsvik, Hakon Johansen, Ole Solheim, Karoline Skogen, Kjell Arne Kvistad, Trond Velde Bogsrud, Kristin Smistad Myrmel, Guro F. Giskeodegard, Tor Ingebrigtsen, Erik Magnus Berntsen, Live Eikenes
Summary: This study aims to evaluate the correlation between anti-3-[F-18]FACBC PET combined with conventional MRI and histomolecular diagnosis in glioma diagnostics. The study found that anti-3-[F-18]FACBC PET has high uptake in the majority of gliomas and improves the accuracy of preoperatively predicted glioma diagnoses.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Biochemistry & Molecular Biology
Luca Filippi, Oreste Bagni, Carmelo Crisafulli, Ivan Cerio, Gabriele Brunotti, Agostino Chiaravalloti, Orazio Schillaci, Franca Dore
Summary: The aim of this study was to evaluate the detection rate (DR) of F-18-FACBC PET/CT and its impact on the management of patients with biochemical recurrence from prostate cancer. The results showed that F-18-FACBC PET/CT had a DR of 76.9% in the entire cohort, with no significant difference among different PSA levels, and had a significant impact on clinical management.
Article
Radiology, Nuclear Medicine & Medical Imaging
Silje Kjarrnes Oen, Knut Johannessen, Lars Kjelsberg Pedersen, Erik Magnus Berntsen, Jon Andre Totland, Hakon Johansen, Trond Velde Bogsrud, Tora S. Solheim, Anna Karlberg, Live Eikenes
Summary: The study aimed to evaluate if combined F-18-FACBC PET/MRI could provide additional diagnostic information compared to MRI alone in brain metastases. The results showed that F-18-FACBC PET/MRI did not improve the detection of brain metastases compared to MRI, but it might detect tumor tissue beyond the contrast enhancement seen on MRI.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Engineering, Biomedical
Luca Filippi, Oreste Bagni, Orazio Schillaci
Summary: Digital PET/CT with F-18-FACBC was evaluated in patients with early castration-resistant prostate cancer, and it was found that F-18-FACBC dPET/CT can detect M1 metastasis in 33.3% of patients, significantly impacting clinical management.
EXPERT REVIEW OF MEDICAL DEVICES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Volker Morath, Michael Heider, Markus Mittelhaeuser, Hannes Rolbieski, Jacob Stroh, Jeremie Calais, Matthias Eiber, Florian Bassermann, Wolfgang A. Weber
Summary: This study compares the tumor uptake of two amino acid analogs in a multiple myeloma model and demonstrates the feasibility of PET imaging with one of the analogs in a multiple myeloma patient. Further investigation shows the potential use of this amino acid analog for imaging multiple myeloma.
Review
Radiology, Nuclear Medicine & Medical Imaging
Courtney Lawhn-Heath, Ali Salavati, Spencer C. Behr, Steven P. Rowe, Jeremie Calais, Wolfgang P. Fendler, Mattias Eiber, Louise Emmett, Michael S. Hofman, Thomas A. Hope
Summary: PSMA-targeted radiopharmaceuticals play a significant role in diagnosing and treating prostate cancer, with higher detection rates compared to conventional imaging and potential to change management plans, contributing positively to the advancement of prostate cancer imaging.
Review
Oncology
Sankarsh Jetty, James Ryan Loftus, Abhinav Patel, Akshya Gupta, Savita Puri, Vikram Dogra
Summary: The imaging of prostate cancer has advanced with the use of molecular imaging, particularly Positron Emission Tomography (PET), replacing traditional CT and MRI for detecting prostate cancer recurrence. PET imaging provides better localization and characterization of disease recurrence, and also plays a role in assessing treatment response and determining patient prognosis and survival. This article reviews the commonly used molecular imaging agents for prostate cancer, focusing on Fluorine-18 fluciclovine (Axumin) and PSMA-ligand agents, including their imaging protocols, interpretation, and potential pitfalls.
Review
Oncology
Ioannis Tsechelidis, Alexis Vrachimis
Summary: PSMA PET, the latest nuclear medicine development, is regarded as the most promising tool for the diagnosis and treatment of prostate malignancy. However, there is still debate and ongoing research regarding its utility and position in guidelines, requiring further studies and trials for clarification.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Beatrice Detti, Maria Grazia Carnevale, Sara Lucidi, Luca Burchini, Saverio Caini, Carolina Orsatti, Niccolo Bertini, Manuele Roghi, Vanessa di Cataldo, Simona Fondelli, Gianluca Ingrosso, Giulio Francolini, Daniele Scartoni, Angela Sardaro, Antonio Pisani, Silvia Scoccianti, Cynthia Aristei, Lorenzo Livi
Summary: Biochemical recurrence (BR) occurs in up to 40% of patients with prostate cancer (PCa) treated with primary radical prostatectomy (RP). Choline PET/CT may show the site of tumor recurrence earlier than traditional imaging methods, particularly at low prostate-specific antigen (PSA) levels, thus influencing subsequent treatment.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi
Summary: Positron emission tomography (PET) imaging has made significant advancements in the diagnosis and treatment of prostate cancer with targeted radiopharmaceuticals. This review focuses on the commonly used PET radiopharmaceuticals in the USA, including prostate-specific membrane antigen (PSMA), fluciclovine, and choline. PET imaging has shown utility over traditional imaging methods in various scenarios, but there are limited studies comparing PET radiopharmaceuticals. PSMA radiopharmaceuticals have unique properties and uses, especially at low prostate-specific antigen (PSA) levels. The choice of PET radiopharmaceutical can impact image interpretation, as some agents have minimal urinary activity while others have high urinary activity.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Lorenzo Cereser, Laura Evangelista, Gianluca Giannarini, Rossano Girometti
Summary: In recent years, prostate magnetic resonance imaging (MRI) has become essential in the primary diagnosis of clinically significant prostate cancer (csPCa). While a negative MRI can prevent unnecessary biopsies, a positive examination prompts targeted biopsy samples, leading to increased csPCa diagnosis with high sensitivity and negative predictive value. The limitations of MRI have sparked discussions on how to stratify biopsy decisions and management based on patient risk and accurately estimate it with clinical and/or imaging findings. Next-generation imaging techniques such as radiolabeled Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) are expanding their indications in primary staging and diagnosis, offering increased sensitivity and serving as problem-solving tools in indeterminate MRI cases. This review summarizes the current evidence on the role of prostate MRI and PSMA-PET in the primary diagnosis of csPCa and their potential interactions.
Article
Radiology, Nuclear Medicine & Medical Imaging
Kai Jannusch, Nils Martin Bruckmann, Janna Morawitz, Matthias Boschheidgen, Harald H. Quick, Ken Herrmann, Wolfgang P. Fendler, Lale Umutlu, Martin Stuschke, Boris Hadaschik, Gerald Antoch, Lars Schimmoeller, Julian Kirchner
Summary: Combined assessment of Ga-68-PSMA-11 PET/MRI improves tumor localization in men with biochemical recurrence. The MRI detected local recurrence of PCa more often whereas (68) Ga-PSMA-11 PET detected lymph node metastases more often, especially for PSA < 1.69 ng/mL.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
Adam M. Kase, Winston Tan, John A. Copland, Hancheng Cai, Ephraim E. Parent, Ravi A. Madan
Summary: Molecular imaging with PSMA PET-CT is more accurate and sensitive than conventional imaging, allowing for earlier diagnosis of advanced prostate cancer. However, overtreatment could be a concern. Understanding the continuum of disease and the accuracy of different imaging modalities is important for patient management.
Article
Urology & Nephrology
Esther Mena, Peter C. Black, Soroush Rais-Bahrami, Michael Gorin, Mohamad Allaf, Peter Choyke
Summary: Among the available PET agents for prostate cancer, PSMA PET has emerged as the leader, showing greater sensitivity and specificity compared to other agents. PSMA PET is likely to have a significant impact on the diagnosis, staging, and management of prostate cancer patients.
WORLD JOURNAL OF UROLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ashesh B. Jani, Eduard Schreibmann, Peter J. Rossi, Joseph Shelton, Karen Godette, Peter Nieh, Viraj A. Master, Omer Kucuk, Mark Goodman, Raghuveer Halkar, Sherrie Cooper, Zhengjia Chen, David M. Schuster
JOURNAL OF NUCLEAR MEDICINE
(2017)
Article
Biochemistry & Molecular Biology
Shuntaro Oka, Masaru Kanagawa, Yoshihiro Doi, David M. Schuster, Mark M. Goodman, Hirokatsu Yoshimura
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2017)
Article
Biochemistry & Molecular Biology
F. Tade, W. G. Wiles, G. Lu, B. Bilir, O. Akin-Akintayo, J. S. Lee, D. Patil, W. Yu, C. Ormenisan Gherasim, B. Fei, C. S. Moreno, A. O. Osunkoya, E. J. Teoh, S. Oka, H. Okudaira, M. M. Goodman, D. M. Schuster
Meeting Abstract
Oncology
E. Schreibmann, D. M. Schuster, P. R. Patel, J. W. Shelton, S. Cooper, H. Raghuveer, A. Jani
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2018)
Article
Radiology, Nuclear Medicine & Medical Imaging
Akinyemi A. Akintayo, O. A. Abiodun-Ojo, C. Weber, J. Sharma, C. Cohen, G. Sica, R. Halkar, M. M. Goodman, D. M. Schuster
MOLECULAR IMAGING AND BIOLOGY
(2019)
Meeting Abstract
Oncology
S. Tian, I. Sethi, X. Yang, A. Da Silva, J. Switchenko, T. K. Owonikoko, D. M. Schuster, W. J. Curran, K. A. Higgins
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Meeting Abstract
Oncology
A. Da Silva, P. Olcott, S. Tian, X. Yang, I. Sethi, S. M. Shirvani, S. Mazin, T. K. Owonikoko, J. D. Bradley, D. M. Schuster, K. A. Higgins
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Meeting Abstract
Oncology
V. R. Dhere, D. M. Schuster, S. Goyal, E. Schreibmann, B. Hershatter, P. J. Rossi, J. W. Shelton, P. R. Patel, A. Jani
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Meeting Abstract
Oncology
S. Tian, J. Switchenko, X. Yang, I. Sethi, A. Da Silva, C. Huntzinger, S. Shirvani, T. K. Owonikoko, D. M. Schuster, W. J. Curran, K. A. Higgins
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2020)
Meeting Abstract
Oncology
P. Olcott, S. M. Shirvani, S. Tian, I. Sethi, X. Yang, A. Da Silva, C. Huntzinger, S. Mazin, T. K. Owonikoko, D. M. Schuster, W. J. Curran, K. A. Higgins
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2020)
Review
Radiology, Nuclear Medicine & Medical Imaging
Baowei Fei, David M. Schuster
AMERICAN JOURNAL OF ROENTGENOLOGY
(2017)
Article
Radiology, Nuclear Medicine & Medical Imaging
Bital Savir-Baruch, Lucia Zanoni, David M. SchusteR
Review
Radiology, Nuclear Medicine & Medical Imaging
Baowei Fei, Peter T. Nieh, Viraj A. Master, Yun Zhang, Adeboye O. Osunkoya, David M. Schuster
CLINICAL AND TRANSLATIONAL IMAGING
(2017)
Review
Radiology, Nuclear Medicine & Medical Imaging
A. Tuba Kendi, Valeria M. Moncayo, Jonathon A. Nye, James R. Galt, Raghuveer Halkar, David M. Schuster
Article
Radiology, Nuclear Medicine & Medical Imaging
Oladunni O. Akin-Akintayo, Ashesh B. Jani, Oluwaseun Odewole, Funmilayo I. Tade, Peter T. Nieh, Viraj A. Master, Leah M. Bellamy, Raghuveer K. Halkar, Chao Zhang, Zhengjia Chen, Mark M. Goodman, David M. Schuster
CLINICAL NUCLEAR MEDICINE
(2017)
